{
  "trial_id": "NCT01984866",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Informed consent Form signed",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Adequate Performance status (ECOG 0-1)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Female patients with unifocal breast tumors (stages II-III, TN, HER2+ or Luminal B)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "very sensitive to neoadjuvant medical treatment (5 to 6 months in accordance with the current standard)",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients who submit clinical-radiologic greater response to the treatment administered (equal to or less than 1.5 cm in NMR residual tumor)",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Ki67<14%",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Excisional biopsy Contraindications",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "45-year-old postmenopausal woman with cytologically confirmed breast cancer, HER2-positive and ER/PR negative.",
  "_meta": {
    "topic_id": "61",
    "trial_id": "NCT01984866",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}